GB1353815A – Analgetic composition
– Google Patents
GB1353815A – Analgetic composition
– Google Patents
Analgetic composition
Info
Publication number
GB1353815A
GB1353815A
GB3207771A
GB3207771A
GB1353815A
GB 1353815 A
GB1353815 A
GB 1353815A
GB 3207771 A
GB3207771 A
GB 3207771A
GB 3207771 A
GB3207771 A
GB 3207771A
GB 1353815 A
GB1353815 A
GB 1353815A
Authority
GB
United Kingdom
Prior art keywords
analgesic
hydroxy
eliminate
methyl
composition
Prior art date
1970-08-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3207771A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1970-08-03
Filing date
1971-07-08
Publication date
1974-05-22
1971-07-08
Application filed by Bristol Myers Co
filed
Critical
Bristol Myers Co
1974-05-22
Publication of GB1353815A
publication
Critical
patent/GB1353815A/en
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/47—Quinolines; Isoquinolines
A61K31/485—Morphinan derivatives, e.g. morphine, codeine
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Abstract
1353815 Analgesic compositions BRISTOLMYERS CO 8 July 1971 [3 Aug 1970] 32077/ 71 Heading A5B Abuse of an addictive, orally active analgesic may be reduced by compounding it with naloxone in an amount sufficient to eliminate its analgesic or euphoric action when administered parenterally but insufficient to eliminate its analgesic or euphoric action when administered orally. Analgesics specified include meperidine, oxymorphone, dextropropoxyphene, methadone, levorphanol, phenazocine, profadol, codeine, -#-2′-hydroxy-2, 9-dimethyl-5-phenyl-6, 7-benzomorphen, -α-5, 9- diethyl-2′-hydroxy-2-methyl-6, 7-benzomorphan, and opium. The composition may also include aspirin, phenacetin, caffeine, acetaminophen, an antihistamine, homatropine, methyl bromide, phenyltoloxamine citrate or a barbiturate.
GB3207771A
1970-08-03
1971-07-08
Analgetic composition
Expired
GB1353815A
(en)
Applications Claiming Priority (1)
Application Number
Priority Date
Filing Date
Title
US6062170A
1970-08-03
1970-08-03
Publications (1)
Publication Number
Publication Date
GB1353815A
true
GB1353815A
(en)
1974-05-22
Family
ID=22030682
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
GB3207771A
Expired
GB1353815A
(en)
1970-08-03
1971-07-08
Analgetic composition
Country Status (9)
Country
Link
US
(1)
US3773955A
(en)
AU
(1)
AU463074B2
(en)
BE
(1)
BE770625A
(en)
DE
(1)
DE2138593A1
(en)
DK
(1)
DK133035B
(en)
FR
(1)
FR2101191B1
(en)
GB
(1)
GB1353815A
(en)
NL
(1)
NL7109388A
(en)
ZA
(1)
ZA714683B
(en)
Cited By (8)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US8518925B2
(en)
2004-06-08
2013-08-27
Euro-Celtique S.A.
Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8673355B2
(en)
1997-12-22
2014-03-18
Purdue Pharma L.P.
Opioid agonist/antagonist combinations
US8822487B2
(en)
1997-12-22
2014-09-02
Purdue Pharma L.P.
Opioid agonist/opioid antagonist/acetaminophen combinations
US8846090B2
(en)
2002-04-05
2014-09-30
Euro-Celtique S.A.
Matrix for sustained, invariant and independent release of active compounds
US8969369B2
(en)
2001-05-11
2015-03-03
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9271940B2
(en)
2009-03-10
2016-03-01
Purdue Pharma L.P.
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2
(en)
2013-07-23
2018-09-11
Euro-Celtique S.A.
Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10258235B2
(en)
2005-02-28
2019-04-16
Purdue Pharma L.P.
Method and device for the assessment of bowel function
Families Citing this family (84)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US3885027A
(en)
*
1971-04-12
1975-05-20
West Laboratories Inc
Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3896226A
(en)
*
1971-11-26
1975-07-22
Lewinstein Evalina
6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3906100A
(en)
*
1973-05-24
1975-09-16
Miles Lab
N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
US4048316A
(en)
*
1974-03-04
1977-09-13
Penn Nathar W
Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4126684A
(en)
*
1976-02-11
1978-11-21
Ciba-Geigy Corporation
4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4457933A
(en)
*
1980-01-24
1984-07-03
Bristol-Myers Company
Prevention of analgesic abuse
JPS56128715A
(en)
*
1980-03-06
1981-10-08
Bristol Myers Co
Analgesic abuse prevention
US4366159A
(en)
*
1981-09-08
1982-12-28
Michael Richard Magruder
Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3216327C1
(en)
*
1982-05-03
1983-05-19
Siempelkamp Gießerei GmbH & Co, 4150 Krefeld
Production of thick-walled shielded transport and storage containers of spherulitic cast iron
EP0116538A4
(en)
*
1982-08-25
1985-04-25
Joel E Bernstein
Method of treating pruritis and composition therefor.
GB8332556D0
(en)
*
1983-12-06
1984-01-11
Reckitt & Colmann Prod Ltd
Analgesic compositions
US4888346A
(en)
*
1986-10-07
1989-12-19
Bernard Bihari
Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5236714A
(en)
*
1988-11-01
1993-08-17
Alza Corporation
Abusable substance dosage form having reduced abuse potential
WO1993004675A1
(en)
1991-09-06
1993-03-18
Mcneilab, Inc.
Composition comprising a tramadol material and acetaminophen and its use
US7027859B1
(en)
1994-09-26
2006-04-11
Alza Corporation
Electrotransport delivery device having improved safety and reduced abuse potential
US5587381A
(en)
*
1995-03-27
1996-12-24
Sinclair; John D.
Method for terminating methadone maintenance through extinction of the opiate-taking responses
HU0100310A3
(en)
1997-12-22
2002-11-28
Euro Celtique Sa
A method of preventing abuse of opioid dosage forms
AU6934400A
(en)
*
1999-08-25
2001-03-19
Barrett R. Cooper
Compositions and methods for treating opiate intolerance
DE60138706D1
(en)
2000-02-08
2009-06-25
Euro Celtique Sa
MISS-IN-HOUSE ORAL OPIOID AGONIST PREPARATIONS
US6716449B2
(en)
2000-02-08
2004-04-06
Euro-Celtique S.A.
Controlled-release compositions containing opioid agonist and antagonist
ATE345112T1
(en)
*
2001-05-11
2006-12-15
Endo Pharmaceuticals Inc
MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE
US7766013B2
(en)
2001-06-05
2010-08-03
Alexza Pharmaceuticals, Inc.
Aerosol generating method and device
WO2003002100A1
(en)
*
2001-06-26
2003-01-09
Farrell John J
Tamper-proof narcotic delivery system
IL159917A0
(en)
2001-07-18
2004-06-20
Euro Celtique Sa
Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1
(en)
2001-08-06
2003-03-06
Curtis Wright
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
NZ530971A
(en)
2001-08-06
2004-08-27
Euro Celtique S
Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists
US20030157168A1
(en)
2001-08-06
2003-08-21
Christopher Breder
Sequestered antagonist formulations
US20030068276A1
(en)
*
2001-09-17
2003-04-10
Lyn Hughes
Dosage forms
US20040126428A1
(en)
*
2001-11-02
2004-07-01
Lyn Hughes
Pharmaceutical formulation including a resinate and an aversive agent
US20030199439A1
(en)
*
2002-04-22
2003-10-23
Simon David Lew
Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
KR20050050615A
(en)
*
2002-04-23
2005-05-31
알자 코포레이션
Transdermal analgesic systems with reduced abuse potential
US10004729B2
(en)
2002-07-05
2018-06-26
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2
(en)
2002-07-05
2013-10-15
Collegium Pharmaceutical, Inc.
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
EP1594467A4
(en)
2002-07-05
2008-10-22
Collegium Pharmaceutical Inc
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7771707B2
(en)
2004-06-12
2010-08-10
Collegium Pharmaceutical, Inc.
Abuse-deterrent drug formulations
US8840928B2
(en)
*
2002-07-05
2014-09-23
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2422775A3
(en)
*
2002-09-20
2012-04-18
Alpharma, Inc.
Sequestering subunit and related compositions and methods
US20040202717A1
(en)
2003-04-08
2004-10-14
Mehta Atul M.
Abuse-resistant oral dosage forms and method of use thereof
CA2519556C
(en)
2003-04-21
2011-01-18
Benjamin Oshlack
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
TWI347201B
(en)
2003-04-21
2011-08-21
Euro Celtique Sa
Pharmaceutical products,uses thereof and methods for preparing the same
US8790689B2
(en)
*
2003-04-30
2014-07-29
Purdue Pharma L.P.
Tamper resistant transdermal dosage form
US20040219195A1
(en)
*
2003-04-30
2004-11-04
3M Innovative Properties Company
Abuse-resistant transdermal dosage form
US7182955B2
(en)
*
2003-04-30
2007-02-27
3M Innovative Properties Company
Abuse-resistant transdermal dosage form
CA2522529C
(en)
2003-04-30
2015-10-20
Purdue Pharma L.P.
Tamper resistant transdermal dosage form
WO2004112756A1
(en)
2003-06-26
2004-12-29
Isa Odidi
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP2269606A3
(en)
2003-10-30
2012-04-25
ALZA Corporation
Transdermal analgesic systems having reduced abuse potential
ATE355103T1
(en)
*
2003-12-09
2006-03-15
Euro Celtique Sa
CO-EXTRUDED SAFETY DOSAGE FORM COMPRISING AN ACTIVE INGREDIENT AND AN ADVERSE AGENT AND PRODUCTION METHOD THEREOF
US8883204B2
(en)
*
2003-12-09
2014-11-11
Purdue Pharma L.P.
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
AU2004305518A1
(en)
*
2003-12-15
2005-07-07
Alexza Pharmaceuticals, Inc.
Treatment of breakthrough pain by drug aerosol inhalation
US20050165038A1
(en)
*
2004-01-22
2005-07-28
Maxwell Gordon
Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP1729730B1
(en)
2004-03-30
2009-01-07
Euro-Celtique S.A.
Tamper resistant dosage form comprising an adsorbent and an adverse agent
US7540286B2
(en)
2004-06-03
2009-06-02
Alexza Pharmaceuticals, Inc.
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604667A1
(en)
*
2004-06-08
2005-12-14
Euro-Celtique S.A.
Opioids for the treatment of the restless leg syndrome
US8394409B2
(en)
2004-07-01
2013-03-12
Intellipharmaceutics Corp.
Controlled extended drug release technology
CN101005833A
(en)
*
2004-08-20
2007-07-25
3M创新有限公司
Transdermal drug delivery device with translucent protective film
US10624858B2
(en)
2004-08-23
2020-04-21
Intellipharmaceutics Corp
Controlled release composition using transition coating, and method of preparing same
CA2594373A1
(en)
*
2005-01-28
2006-08-03
Euro-Celtique S.A.
Alcohol resistant dosage forms
TW200640526A
(en)
*
2005-02-24
2006-12-01
Alza Corp
Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1695700A1
(en)
2005-02-28
2006-08-30
Euro-Celtique S.A.
Dosage form containing oxycodone and naloxone
WO2006124584A2
(en)
*
2005-05-13
2006-11-23
Alza Corporation
Multilayer drug delivery system with barrier against reservoir material flow
WO2006133102A2
(en)
*
2005-06-03
2006-12-14
Trans-Dermal Patents Company, Llc
Agent delivery system and uses of the same
US20090143761A1
(en)
*
2005-06-03
2009-06-04
Transdermal Patents Company, Llc
Agent delivery system and uses of same
US20100210732A1
(en)
*
2005-11-02
2010-08-19
Najib Babul
Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
WO2007087452A2
(en)
*
2006-01-27
2007-08-02
Theraquest Biosciences, Llc
Abuse resistant and extended release formulations and method of use thereof
WO2008134071A1
(en)
*
2007-04-26
2008-11-06
Theraquest Biosciences, Inc.
Multimodal abuse resistant extended release formulations
US8329744B2
(en)
*
2005-11-02
2012-12-11
Relmada Therapeutics, Inc.
Methods of preventing the serotonin syndrome and compositions for use thereof
US10064828B1
(en)
2005-12-23
2018-09-04
Intellipharmaceutics Corp.
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810670A1
(en)
*
2006-01-19
2007-07-25
Holger Lars Hermann
Combination of Polamidone and Naloxone for the treatment of drug addiction
ZA200807571B
(en)
2006-03-01
2009-08-26
Ethypharm Sa
Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
WO2007112581A1
(en)
2006-04-03
2007-10-11
Isa Odidi
Controlled release delivery device comprising an organosol coat
US10960077B2
(en)
2006-05-12
2021-03-30
Intellipharmaceutics Corp.
Abuse and alcohol resistant drug composition
US20070278289A1
(en)
*
2006-05-31
2007-12-06
Toshiba Tec Kabushiki Kaisha
Payment adjusting apparatus and program therefor
MX2008016372A
(en)
2006-06-19
2009-05-28
Alpharma Inc
Pharmaceutical compositions.
EP1897543A1
(en)
2006-08-30
2008-03-12
Euro-Celtique S.A.
Buprenorphine- wafer for drug substitution therapy
ES2594867T3
(en)
2007-03-09
2016-12-23
Alexza Pharmaceuticals, Inc.
Heating unit for use in a drug delivery device
US7748244B2
(en)
*
2007-09-14
2010-07-06
Schlage Lock Company
Deadbolt lock assembly
US20110251229A1
(en)
*
2007-10-30
2011-10-13
The Regents Of The University Of Colorado
(+)-opioids and methods of use
US20100239523A1
(en)
*
2007-10-30
2010-09-23
The Regents Of The University Of Colorado
Tlr modulators and methods for using the same
US8623418B2
(en)
2007-12-17
2014-01-07
Alpharma Pharmaceuticals Llc
Pharmaceutical composition
US10668060B2
(en)
2009-12-10
2020-06-02
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2827273A1
(en)
2011-02-17
2012-08-23
QRxPharma Ltd.
Technology for preventing abuse of solid dosage forms
WO2016203061A1
(en)
2015-09-03
2016-12-22
Acino Pharma Ag
Reduction in deallylation of naloxone during storage of a sustained-release formulation containing naloxone
US9737530B1
(en)
2016-06-23
2017-08-22
Collegium Pharmaceutical, Inc.
Process of making stable abuse-deterrent oral formulations
US10532385B2
(en)
2016-06-29
2020-01-14
Disposerx, Inc.
Disposal of medicaments
1970
1970-08-03
US
US00060621A
patent/US3773955A/en
not_active
Expired – Lifetime
1971
1971-07-07
NL
NL7109388A
patent/NL7109388A/xx
unknown
1971-07-08
GB
GB3207771A
patent/GB1353815A/en
not_active
Expired
1971-07-15
ZA
ZA714683A
patent/ZA714683B/en
unknown
1971-07-28
BE
BE770625A
patent/BE770625A/en
unknown
1971-07-30
AU
AU31856/71A
patent/AU463074B2/en
not_active
Expired
1971-08-02
FR
FR7128227A
patent/FR2101191B1/fr
not_active
Expired
1971-08-02
DE
DE19712138593
patent/DE2138593A1/en
active
Pending
1971-08-03
DK
DK378571AA
patent/DK133035B/en
unknown
Cited By (26)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US8932630B1
(en)
1997-12-22
2015-01-13
Purdue Pharma L.P
Opioid agonist/antagonist combinations
US8673355B2
(en)
1997-12-22
2014-03-18
Purdue Pharma L.P.
Opioid agonist/antagonist combinations
US8822487B2
(en)
1997-12-22
2014-09-02
Purdue Pharma L.P.
Opioid agonist/opioid antagonist/acetaminophen combinations
US9205082B2
(en)
1997-12-22
2015-12-08
Purdue Pharma L.P.
Opioid agonist/antagonist combinations
US9511066B2
(en)
2001-05-11
2016-12-06
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9345701B1
(en)
2001-05-11
2016-05-24
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US8969369B2
(en)
2001-05-11
2015-03-03
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9056051B2
(en)
2001-05-11
2015-06-16
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9084729B2
(en)
2001-05-11
2015-07-21
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9161937B2
(en)
2001-05-11
2015-10-20
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9168252B2
(en)
2001-05-11
2015-10-27
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9480685B2
(en)
2001-05-11
2016-11-01
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9358230B1
(en)
2001-05-11
2016-06-07
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9283216B2
(en)
2001-05-11
2016-03-15
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US9283221B2
(en)
2001-05-11
2016-03-15
Purdue Pharma L.P.
Abuse-resistant controlled-release opioid dosage form
US8846091B2
(en)
2002-04-05
2014-09-30
Euro-Celtique S.A.
Matrix for sustained, invariant and independent release of active compounds
US8846090B2
(en)
2002-04-05
2014-09-30
Euro-Celtique S.A.
Matrix for sustained, invariant and independent release of active compounds
US9555000B2
(en)
2002-04-05
2017-01-31
Purdue Pharma L.P.
Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2
(en)
2002-04-05
2017-05-23
Purdue Pharma L.P.
Matrix for sustained, invariant and independent release of active compounds
US9907793B2
(en)
2002-04-05
2018-03-06
Purdue Pharma L.P.
Pharmaceutical preparation containing oxycodone and naloxone
US10420762B2
(en)
2002-04-05
2019-09-24
Purdue Pharma L.P.
Pharmaceutical preparation containing oxycodone and naloxone
US8518925B2
(en)
2004-06-08
2013-08-27
Euro-Celtique S.A.
Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US10258235B2
(en)
2005-02-28
2019-04-16
Purdue Pharma L.P.
Method and device for the assessment of bowel function
US9271940B2
(en)
2009-03-10
2016-03-01
Purdue Pharma L.P.
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9820983B2
(en)
2009-03-10
2017-11-21
Purdue Pharma L.P.
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2
(en)
2013-07-23
2018-09-11
Euro-Celtique S.A.
Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
Also Published As
Publication number
Publication date
ZA714683B
(en)
1972-04-26
FR2101191A1
(en)
1972-03-31
DE2138593A1
(en)
1972-03-30
NL7109388A
(en)
1972-02-07
AU3185671A
(en)
1973-02-01
DK133035B
(en)
1976-03-15
FR2101191B1
(en)
1975-02-07
BE770625A
(en)
1972-01-28
AU463074B2
(en)
1975-07-17
US3773955A
(en)
1973-11-20
Similar Documents
Publication
Publication Date
Title
GB1353815A
(en)
1974-05-22
Analgetic composition
Hosobuchi et al.
1978
The analgesic activity of human! b-endorphin in man.
AU559218B2
(en)
1987-02-26
Improved analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
ES8308698A1
(en)
1983-10-01
Topical pharmaceutical compositions
EP0663401A4
(en)
1996-06-26
Morphinan derivative and medicinal use.
EP0171742A3
(en)
1987-12-16
Transdermal delivery of opioids
GB1092394A
(en)
1967-11-22
Benzomorphan derivatives and processes for their production
IL60095A
(en)
1982-12-31
Synergistic analgesic pharmaceutical compositions comprising nalbuphine and acetaminophen
AU2955784A
(en)
1985-01-03
Topical pharmaceutical composition with penetration enhencing properties
NZ331119A
(en)
2000-05-26
Isoquinolines useful as analgesics
Eddy
1969
Codeine and its alternates for pain and cough relief
Jacob et al.
1977
Opioid antagonists, endogenous ligands and nocioception.
GR3022995T3
(en)
1997-07-30
Pharmaceutical composition consisting of flupirtin and morphine for the treatment of pain and to avoid a morphine addiction
NZ332215A
(en)
2000-09-29
Transdermally administered dextromethorphan as antitussive agent
Dykstra et al.
1977
Electric shock titration: Effects of morphine, methadone, pentazocine, nalorphine, naloxone, diazepam and amphetamine.
GB1507418A
(en)
1978-04-12
Process for producing tablets and suppositories and a composition for use therein
EP0193354A3
(en)
1989-04-05
Analgesic composition
DE2861019D1
(en)
1981-11-26
Tetrapeptides, methods for their preparation and their use in analgesic compositions
GB1234508A
(en)
1971-06-03
GB1464512A
(en)
1977-02-16
Analgestic formulations having enhanced therapeutic activity
CA989834A
(en)
1976-05-25
3,4-dihydro-6,7-substituted-2,3-lower alkyl-4-oxo-1(2h)-quinazolecarboxylic acid derivatives useful as analgesic and tranquilizer agents
Kantor et al.
1984
Oral naluphine in postpartum pain
IE45899L
(en)
1978-05-02
TRANS-5a-ARYL-DECAHYDROBENZAZEPINES
ES456280A1
(en)
1978-04-16
Alpha-2,5,9-trimethyl-benzo(b)thiene(2,3-f)morphan and precursor thereof
CA2048894A1
(en)
1992-02-11
Method of treating mast cell disease
Legal Events
Date
Code
Title
Description
1974-10-02
PS
Patent sealed [section 19, patents act 1949]
1978-02-08
PLNP
Patent lapsed through nonpayment of renewal fees
